LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

McKesson Announces Third Quarter Fiscal 2024 Earnings Release Date and Participation in January Conference

December 27, 2023 | Last Trade: US$597.17 12.79 2.19

IRVING, Texas / Dec 27, 2023 / Business Wire / McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

The live webcast for each event will be available on McKesson’s Investor Relations website at http://investor.mckesson.com, along with the company’s earnings release, financial tables and slide presentation.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page